Dr. Yu and Dr. Patel provide an overview of current standards and recent advances in the treatment landscape for EGFR-mutated NSCLC, emphasizing the critical role of comprehensive genomic profiling in guiding optimal therapy selection and sequencing.
Dr. Gregory Gan presents Case 4, featuring a 71-year-old diagnosed with Stage IIIA NSCLC experiencing pneumonitis following Chemo-IO treatment, prompting a discussion with expert insight on the monitoring and management of this condition.
Dr. Gregory Gan introduces Case 2, involving a 70-year-old former smoker with Stage IIIB NSCLC and a PD-L1 level of 10%, prompting discussion with emphasis on the importance of shared decision-making with the patient and their caregivers.
Benjamin Maughan, MD, PharmD, examines efficacy outcomes from the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib in metastatic clear cell RCC, including how overall survival, progression free survival, and response rates compare across different baseline tumor size groups.
Elizabeth Plimack, MD, discusses the long term follow up data from the Checkmate 214 study evaluating nivolumab plus ipilimumab versus sunitinib in first line treatment of clear cell renal cell carcinoma, including overall survival, progression free survival, response rates, and safety data.
Focusing on patient-centered care, Rana R. McKay, MD, and the Oncology Brothers discuss the role of PSA and PSMA PET scans in guiding treatment for patients with prostate cancer.
Medical oncologists provide clinical insights on treatment paradigms for patients with castration-resistant prostate cancer, highlighting how next-generation sequencing informs treatment decisions.
The Oncology Brothers and Rana R. McKay, MD, have a comprehensive discussion on the treatment of patients with castration-sensitive prostate cancer.
Rana R. McKay, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the treatment algorithm for patients with localized prostate cancer.
Rani Bansal, MD, discusses progressive developments in treating brain metastases in HER2-positive breast cancer, highlighting insights from the TUXEDO and DEBORAH trials, and examines the potential role of T-DXd in managing leptomeningeal disease.
Rani Bansal, MD, discusses the case of a 54-year-old post-menopausal patient who develops liver and brain metastases after undergoing prior therapy with trastuzumab/pertuzumab and T-DM1.
Heather Moore, CPP, PharmD examines the role of topical diclofenac gel in the management of hand and foot syndrome associated with capecitabine, highlighting key insights from the D-TORCH trial.
Heather Moore, CPP, PharmD, shares expert insights on the effective management of adverse effects related to tucatinib and other HER2 tyrosine kinase inhibitors (TKIs).
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Michael Foote, MD, presents the case of a 50-year-old man with stage III colorectal cancer, highlighting the role of MRD testing in patient monitoring and treatment management.
GI medical oncologists discuss MRD testing practices in colorectal cancer and provide insights on challenges associated with testing.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
The panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.
A panel of oncology experts discuss recent advancements surrounding novel therapies for CLL, exploring their potential impact on future treatment paradigms.
Dr. Gregory Gan introduces Case 2, featuring an 82-year-old former smoker with poorly differentiated lung adenocarcinoma and a PD-L1 level of 85%, initiating a conversation on the role of a multidisciplinary approach to treatment and consideration factors for surgical and radiotherapy interventions.
Gregory Gan, MD, presents Case 1 involving a 72-year-old former smoker with Stage-IIIA NSCLC and a PD-L1 level of 90%, initiating a discussion on the treatment and management of the case.
Carey Anders, MD, offers insights into the BRIDGET trial, a study investigating the role of tucatinib in the prevention of secondary brain metastases in patients with advanced HER2-positive breast cancer.
Carey Anders, MD, examines strategies for treating stable and active brain metastases in individuals with advanced HER2-positive breast cancer, highlighting key data from the HER2CLIMB trial.
Carey Anders, MD, discusses the scenario of a 34-year-old patient diagnosed with HER2-positive breast cancer, who develops brain metastases after undergoing initial therapy with dual HER2 blockade.
Heather Moore, CPP, PharmD, presents a comprehensive summary of targeted therapies for HER2-positive breast cancer and provides expert insights into the management of adverse effects associated with these treatments.
Virginia Kaklamani, MD, offers clinical insights on treatment toxicity considerations in HR+ breast cancer, and the Oncology Brothers outline key takeaways from the discussion.
Medical oncologists provide comprehensive insights on the standard-of-care treatment practices for patients with advanced/metastatic HR+ breast cancer.
Arvind N. Dasari, MD, MS, provides clinical insights on MRD testing modalities, highlighting factors that inform the decision on which platform to use in practice.
The Oncology Brothers and Virginia Kaklamani, MD, outline the treatment algorithm for patients with locally advanced HR+ breast cancer.
Virginia Kaklamani, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss treatment paradigms for patients with early-stage HR+ breast cancer, highlighting the differences in treatment for premenopausal and postmenopausal patients.
